NCT00098345View on ClinicalTrials.gov

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

February 29, 2008

Study Completion Date

April 19, 2017

Conditions
Thyroid Cancer
Interventions
DRUG

ZD6474 (vandetanib)

oral once daily tablet

Trial Locations (6)

Unknown

Research Site, San Francisco

Research Site, New Haven

Research Site, New York

Research Site, Durham

Research Site, Houston

Research Site, Villejuif

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00098345 - Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer | Biotech Hunter | Biotech Hunter